Company profile: Orionis Biosciences
1.1 - Company Overview
Company description
- Provider of biotechnology platforms for healthcare innovation, including the A-Kine platform for engineering cytokines with targeted cell selectivity and controlled activity for cancer immunotherapy, and the Allo-Glue platform for discovering and designing small molecule molecular glues to modulate or degrade disease targets.
Products and services
- Allo-Glue Platform: Modular chemical biology platform that develops small-molecule molecular glues to modulate or degrade disease targets, integrating discovery and design workflows to enable target-specific modulation or degradation
- A-Kine Platform: Custom-engineered biologics platform that engineers cytokines with targeted cell selectivity and controlled activity for cancer immunotherapy, enabling selective engagement of specific cell populations and precisely tuned signaling effects
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Orionis Biosciences
IOmet Pharma
HQ: United Kingdom
Website
- Description: Provider of novel small-molecule medicines for the treatment of cancer, discovered and developed in the UK with particular emphasis on cancer immunotherapy and cancer metabolism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IOmet Pharma company profile →
Dako
HQ: Denmark
Website
- Description: Provider of reagents, instruments, and software for cancer diagnostics to hospital and research laboratories, offering pathology solutions including diagnostic antibodies, IHC/ISH and flow cytometry reagents; staining and image analysis instruments; molecular and companion diagnostics; and pharmacodiagnostic kits (pharmDx).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dako company profile →
Ajax Therapeutics
HQ: United States
Website
- Description: Provider of therapies targeting cytokine signaling in hematologic malignancies, including AJ1-10502, a next-generation Type II JAK2 inhibitor for myeloproliferative neoplasms with improved efficacy and selectivity over Type I JAK2 inhibitors, and developer of a pipeline of selectively targeted small molecules via a partnership with Schrödinger using advanced computational chemistry and structure-based technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ajax Therapeutics company profile →
Kinnate Biopharma
HQ: United States
Website
- Description: Provider of precision oncology therapeutics for genomically-defined cancers, leveraging structure-based drug discovery and translational research. Pipeline includes exarafenib (KIN-2787), a pan-RAF inhibitor for BRAF/NRAS-driven tumors; KIN-3248 targeting FGFR2/3 alterations in intrahepatic cholangiocarcinoma and urothelial carcinoma; KIN-8741, a selective c-MET inhibitor; and a potentially brain-penetrant CDK4 inhibitor for adult solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kinnate Biopharma company profile →
Oric Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical treatments that target the causes of therapeutic resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oric Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Orionis Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Orionis Biosciences
2.2 - Growth funds investing in similar companies to Orionis Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Orionis Biosciences
4.2 - Public trading comparable groups for Orionis Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →